SIGA Key Statistics, Chart & Performance
The current stock price of SIGA is 6.28 USD. In the past month the price decreased by -23.34%. In the past year, price decreased by -10.34%.
SIGA Latest News, Press Relases and Analysis
SIGA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 46.18 | 959.94B | ||
| JNJ | JOHNSON & JOHNSON | 19.5 | 487.74B | ||
| MRK | MERCK & CO. INC. | 11.49 | 251.35B | ||
| PFE | PFIZER INC | 8.02 | 145.87B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.91 | 105.61B | ||
| ZTS | ZOETIS INC | 19 | 53.10B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.53 | 22.60B | ||
| VTRS | VIATRIS INC | 4.6 | 12.34B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.78 | 10.86B | ||
| CORT | CORCEPT THERAPEUTICS INC | 96.97 | 8.98B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.48B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.25B |
Related stock screener links
About SIGA
Company Profile
SIGA Technologies, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of solutions for medical needs and biothreats. The company is headquartered in New York City, New York and currently employs 46 full-time employees. The firm is focused on the development of medicines to treat and prevent infectious diseases. Its flagship product, TPOXX (tecovirimat), is an antiviral medicine approved in the United States and Canada for the treatment of smallpox and authorized in Europe, the United Kingdom, and Japan for the treatment of smallpox, monkeypox (mpox), cowpox, and vaccinia complications. TPOXX specifically inhibits the activity of a protein called VP37, found on the surface of all orthopoxviruses. This prevents the virus from leaving infected cells, slowing the spread of the infection and limiting it to a point where the immune system can clear the virus. The European Medicines Agency and United Kingdom approvals include labeling for oral tecovirimat indicating its use for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox.
Company Info
SIGA TECHNOLOGIES INC
31 East 62Nd Street
New York City NEW YORK 10065 US
CEO: Phillip L. Gomez
Employees: 46
Phone: 12126729100
SIGA TECHNOLOGIES INC / SIGA FAQ
Can you describe the business of SIGA TECHNOLOGIES INC?
SIGA Technologies, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of solutions for medical needs and biothreats. The company is headquartered in New York City, New York and currently employs 46 full-time employees. The firm is focused on the development of medicines to treat and prevent infectious diseases. Its flagship product, TPOXX (tecovirimat), is an antiviral medicine approved in the United States and Canada for the treatment of smallpox and authorized in Europe, the United Kingdom, and Japan for the treatment of smallpox, monkeypox (mpox), cowpox, and vaccinia complications. TPOXX specifically inhibits the activity of a protein called VP37, found on the surface of all orthopoxviruses. This prevents the virus from leaving infected cells, slowing the spread of the infection and limiting it to a point where the immune system can clear the virus. The European Medicines Agency and United Kingdom approvals include labeling for oral tecovirimat indicating its use for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox.
What is the current price of SIGA stock?
The current stock price of SIGA is 6.28 USD. The price increased by 0.64% in the last trading session.
Does SIGA TECHNOLOGIES INC pay dividends?
SIGA TECHNOLOGIES INC (SIGA) has a dividend yield of 9.9%. The yearly dividend amount is currently 0.6.
What is the ChartMill technical and fundamental rating of SIGA stock?
SIGA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 8 out of 10.
What is the ex-dividend date for SIGA stock?
The next ex-dividend date for SIGA TECHNOLOGIES INC (SIGA) is April 29, 2025.
What is the employee count for SIGA stock?
SIGA TECHNOLOGIES INC (SIGA) currently has 46 employees.
Can you provide the market cap for SIGA TECHNOLOGIES INC?
SIGA TECHNOLOGIES INC (SIGA) has a market capitalization of 449.71M USD. This makes SIGA a Small Cap stock.
SIGA Technical Analysis
SIGA Fundamental Analysis
ChartMill assigns a fundamental rating of 8 / 10 to SIGA. SIGA has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company.
SIGA Financial Highlights
Over the last trailing twelve months SIGA reported a non-GAAP Earnings per Share(EPS) of 1.02. The EPS decreased by -15% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 43.37% | ||
| ROA | 32.26% | ||
| ROE | 36.72% | ||
| Debt/Equity | 0 |
SIGA Forecast & Estimates
For the next year, analysts expect an EPS growth of -35.32% and a revenue growth -34.25% for SIGA